Alexander Raufi, MD
Hematology & Oncology · Providence, RINPI 1124461181
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $681 of the $781 with a category attached, or 87.2%. 7 manufacturers reported payments, led by AstraZeneca at 43.8% of the total.
Across 10 payments — averaging $78.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$342
- Ipsen Biopharmaceuticals, Inc$115
- Astrazeneca UK Limited$100
- Genentech, Inc.$71
- F. Hoffmann-la Roche AG$61
- Genentech USA, Inc.$46
- plus $45 from 1 others
Across 300 payments — averaging $5556.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$683K
- AstraZeneca$551K
- Genentech, Inc.$406K
- Sirtex Medical Inc$27K
What the payments were for
- Food & beverage$68187%
- Education$10013%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 4 | $342 |
| Ipsen Biopharmaceuticals, Inc | 1 | $115 |
| Astrazeneca UK Limited | 1 | $100 |
| Genentech, Inc. | 1 | $71 |
| F. Hoffmann-la Roche AG | 1 | $61 |
| Genentech USA, Inc. | 1 | $46 |
| Daiichi Sankyo Inc. | 1 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOMATULINE DEPOT$115
- ONIVYDE$115
- SOLIRIS$100
How this compares
$781 in reported general payments places this provider in the 60th percentile of 68 hematology & oncology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 16 | $7,003 |
| Ondansetron Hcl | 56 | $767 |
| Prochlorperazine Maleate | 48 | $445 |
| Omeprazole | 23 | $433 |
| Dexamethasone | 75 | $285 |
| Mirtazapine | 18 | $208 |
| Oxycodone Hcl | 11 | $100 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Providence
- William SikovProvidence$156K
- Ritesh RathoreProvidence$148K
- Anthony MegaProvidence$65K
- Adam OlszewskiProvidence$63K
- Hina KhanProvidence$34K
- Peter BarthProvidence$29K
- Thomas OllilaProvidence$19K
- John ReaganProvidence$18K
- Jennifer GassProvidence$16K
- Matthew HadfieldProvidence$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.